Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

71°
- Benton, AR (72018)
  Today
  
  Cloudy skies. A stray shower or thunderstorm is possible. High 79F. Winds SSW at 10 to 20 mph..
  
  Tonight
  
  Partly cloudy skies early will give way to cloudy skies late. A stray shower or thunderstorm is possible. Low 68F. Winds S at 10 to 15 mph.
  
  Updated: April 2, 2026 @ 12:42 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Astellas Pharma ADR (OP:ALPMY)

16.55 -0.23 (-1.37%)

Streaming Delayed Price Updated: 2:10 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma ADR

< Previous 1 2 3 Next >

Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients ↗

February 15, 2022

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) announced the initial results from Cohort H of the EV-103 trial investigating PADCEV (...

Via Benzinga

Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact ↗

December 02, 2021

Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY...

Via Benzinga

4 No-Brainer Pharmaceutical Stocks to Buy in October ↗

September 27, 2021

While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical...

Via Talk Markets

Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan ↗

September 27, 2021

Japan's Ministry of Health, Labor, and Welfare (MHLW) has approved Astellas Pharma Inc's (OTC: ALPMF) Padcev (enfortumab vedotin) for radically...

Via Benzinga

Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold ↗

September 14, 2021

Astellas Pharma Inc (OTC: ALPMF) has seen the fourth death in its experimental gene therapy trial gained through a $3 billion buyout of Audentes Therapeutics...

Via Benzinga

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout ↗

September 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...

Via Benzinga

See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial ↗

September 01, 2021

Astellas Pharma Inc (OTC: ALPMF) has voluntarily paused screening and dosing of additional participants in its ASPIRO trial evaluating AT132 gene therapy in...

Via Benzinga

After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat ↗

August 20, 2021

The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...

Via Benzinga

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering ↗

September 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...

Via Benzinga

Here's What Recent News From the FDA Means for AstraZeneca ↗

August 20, 2021

Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.

Via The Motley Fool

FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial ↗

August 11, 2021

The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease...

Via Benzinga

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The IPO Recap – Party Is Everything But Over ↗

July 28, 2021

Last week's 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled IPOs, marking the fifth week in 2021 with...

Via Benzinga

Topics Initial Public Offering

Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer ↗

July 12, 2021

The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat...

Via Benzinga

The 2 Best Pharma Stocks to Buy on Dips ↗

June 23, 2021

Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off.

Via Talk Markets

Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows ↗

May 11, 2021

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-...

Via Benzinga

Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics ↗

May 03, 2021

Cytokinetics Inc (NASDAQ: CYTK) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and...

Via Benzinga

Topics Regulatory Compliance

Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold ↗

April 27, 2021

In a financial notice posted earlier today, Astellas Pharma Inc (OTCMKTS: ALPMY) said it was taking an impairment loss of ¥58.8 billion ($540 million) because of...

Via Benzinga

FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat ↗

April 07, 2021

FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company’s anemia treatment in chronic kidney...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Astellas Pharma ADR (OP:ALPMY)

All News about Astellas Pharma ADR

Sections

Services

Follow Us